Weight Loss Without Injections: What's Actually Available in the UK

Step 1: Understanding what oral semaglutide actually is

Semaglutide is the active ingredient in both Wegovy injections and Wegovy tablets. In both forms it works as a GLP-1 receptor agonist, acting on receptors involved in appetite regulation and slowing how quickly the stomach empties. The result, for most people, is eating less without a constant internal negotiation with hunger.

The tablet version uses an absorption enhancer called SNAC to help semaglutide pass through the stomach lining and into the bloodstream. Without it, the protein-based molecule would simply be digested before doing anything useful. This formulation step is what makes an oral GLP-1 possible at all, the science behind it is quite different from a standard tablet.

The MHRA approved Wegovy tablets on 11 June 2026, making the UK the first country in Europe to license an oral GLP-1 for weight management. The dosing ladder runs from 1.5 mg up through 4 mg and 9 mg to the 25 mg maintenance dose, spending at least a month at each level. For anyone already established on the 2.4 mg weekly injection, a prescriber may consider moving directly to the 25 mg tablet, though that decision sits with the clinician. The NHS medicines page for semaglutide covers the drug's background in plain language.

Step 2: Building the daily routine before any weight loss begins

The tablet's absorption depends on a strict morning ritual, and getting it right matters. You take it first thing, on a completely empty stomach, with no more than about 120 ml of plain water, roughly half a small glass. Then you wait a full 30 minutes before eating, drinking anything else (coffee included), or taking other oral medicines. Swap the order and the absorption drops sharply.

The practical upside is that storage is simple. Unlike the injection pens, which live in the fridge, the tablets sit at room temperature, on the kitchen counter, in a handbag, or tucked in a desk drawer. There is no cold chain to manage, no planning around a pharmacy's opening hours before a holiday, no explaining a travel case full of ice packs.

People who tried GLP-1 injections and found the weekly injection uncomfortable, or who simply prefer a tablet as part of a morning routine, often find this the more manageable option. Exploring whether injection discomfort was the main barrier is worth doing before deciding, because both routes carry the same clinical supervision requirements.

Step 3: Reading the evidence with clear eyes

The phase 3 trial behind the MHRA approval was OASIS 4: 307 adults with obesity or overweight plus at least one weight-related condition, over 64 weeks, compared against placebo alongside lifestyle changes. Average weight loss in the semaglutide group was around 13.6%, versus roughly 2.4% for placebo. Among participants who stayed fully adherent throughout, the figure reached approximately 17%. That second number is frequently quoted; it is real, but it applies to the adherent subgroup, not the overall population enrolled.

For comparison, the Wegovy injection at 2.4 mg produced around 15% average loss over 68 weeks in the STEP 1 trial, and tirzepatide (Mounjaro, a dual GIP and GLP-1 agonist) reached around 20–21% at its highest dose over 72 weeks. The tablet sits below those figures on average, though the full clinical picture (tolerability, preference, contraindications, lifestyle) shapes the right choice for any individual. A useful overview of the evidence landscape sits in NICE's appraisal of tirzepatide (TA1026), which also discusses the indirect comparison between treatments.

Side effects follow a GLP-1 pattern: nausea, vomiting, diarrhoea and constipation are the most common, and the OASIS 4 trial reported gastrointestinal effects in around 74% of the semaglutide group. Most were mild to moderate and settled over time, particularly as the dose increased gradually. If you are weighing up options and want to understand which injectable treatments tend to have a more favourable tolerability profile, our guide to finding the best weight loss injection without side effects sets out what the evidence currently shows. Anyone experiencing severe, persistent stomach pain that spreads to the back should seek medical help promptly; the MHRA highlighted acute pancreatitis as a known, though infrequent, risk for this class of medicines.

Step 4: Getting a prescription and what the assessment covers

Wegovy tablets are a prescription-only medicine. The licensed criteria require adults with a BMI of 30 or above, or a BMI of 27–29.9 alongside at least one weight-related condition such as high blood pressure, high cholesterol, type 2 diabetes or obstructive sleep apnoea. Lower thresholds apply for some ethnic backgrounds under UK guidance. A prescriber reviews the full picture: your health history, any existing medicines, contraindications, and whether a tablet suits you better than an injection.

People sometimes ask whether they can access weight-loss medicines without a consultation, the answer is straightforwardly no, for any licensed route. The assessment is where safety actually lives. At nume, at our pharmacy, prescribers review consultations the same day they arrive; there is no algorithm making that call, only a GPhC-registered clinician reading your answers.

The tablet is not yet available on the NHS, which would require a NICE appraisal first. For now it is private prescription only. If you want to understand the full range of weight-loss treatment options before committing to anything, that is a reasonable place to start. Those who have already considered injections and want to weigh the two routes can find a straightforward comparison on our weight-loss injection page, and if you have been wondering whether weight loss injections work without exercise, our dedicated page looks at what the clinical trials actually tell us about that question. And if the question is specifically about what happens in the NHS system, our guide to how to get weight-loss injections explains both routes clearly.

If you are ready to find out whether Wegovy tablets are clinically suitable for you, speaking to our prescribers is the natural next step. A free consultation takes a few minutes and is reviewed the same day.